[go: up one dir, main page]

GT200200191A - Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados - Google Patents

Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Info

Publication number
GT200200191A
GT200200191A GT200200191A GT200200191A GT200200191A GT 200200191 A GT200200191 A GT 200200191A GT 200200191 A GT200200191 A GT 200200191A GT 200200191 A GT200200191 A GT 200200191A GT 200200191 A GT200200191 A GT 200200191A
Authority
GT
Guatemala
Prior art keywords
diabetes
derivatives
naftiridine
treatment
related disorders
Prior art date
Application number
GT200200191A
Other languages
English (en)
Inventor
Yamin Wang
William H Bullock
Libing Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200191A publication Critical patent/GT200200191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE 1,6NAFTIRIDINA DE FORMULA GENERAL (I) EN DONDE R1',R2',R3',R4',R5',R6',R7',R8', SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. LA ESTRATEGIA PRINCIPAL DE ESTOS COMPUESTOS SE BASA EN EL MECANISMO DE SEÑALIZACION DEL ADENOSIN MONOFOSFATO CICLICO (AMPC) Y SUS EFECTOS SOBRE LA SECRECION DE INSULINA POR LO QUE SON DE UTILIDAD EN CASOS DE DIABETES.
GT200200191A 2001-09-26 2002-09-26 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados GT200200191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32451101P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
GT200200191A true GT200200191A (es) 2003-05-23

Family

ID=23263913

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200200194A GT200200194A (es) 2001-09-26 2002-09-26 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
GT200200191A GT200200191A (es) 2001-09-26 2002-09-26 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT200200194A GT200200194A (es) 2001-09-26 2002-09-26 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Country Status (24)

Country Link
US (5) US6900205B2 (es)
EP (2) EP1432711A1 (es)
JP (2) JP2005504808A (es)
KR (2) KR20040041177A (es)
CN (2) CN1578780A (es)
AR (2) AR037504A1 (es)
BR (2) BR0212829A (es)
CA (2) CA2461132A1 (es)
CO (2) CO5560542A2 (es)
EC (2) ECSP045084A (es)
GT (2) GT200200194A (es)
HN (1) HN2002000275A (es)
HR (2) HRP20040309A2 (es)
HU (2) HUP0402310A2 (es)
IL (2) IL160708A0 (es)
MA (2) MA26344A1 (es)
MX (2) MXPA04002136A (es)
NO (2) NO20041560L (es)
PE (2) PE20030601A1 (es)
PL (2) PL369531A1 (es)
RU (2) RU2004112787A (es)
UY (2) UY27457A1 (es)
WO (2) WO2003027112A1 (es)
ZA (2) ZA200403064B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504808A (ja) * 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2005018567A2 (en) * 2003-08-22 2005-03-03 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
US7728141B2 (en) * 2003-11-04 2010-06-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP1771456A2 (fr) * 2004-07-30 2007-04-11 Palumed SA Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025303A2 (en) * 2005-08-26 2007-03-01 The Regents Of The University Of California Non-steroidal antiandrogens
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US10017827B2 (en) 2007-04-04 2018-07-10 Nidera S.A. Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
ES2561298T3 (es) * 2011-07-12 2016-02-25 F. Hoffmann-La Roche Ag Compuestos de aminometilquinolona
TWI648277B (zh) 2011-09-02 2019-01-21 美商英塞特控股公司 作為ｐｉ３ｋ抑制劑之雜環基胺
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
EP2970273B1 (en) 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA3285092A1 (en) 2015-02-27 2025-11-29 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2017025913A1 (en) 2015-08-10 2017-02-16 VIIV Healthcare UK (No.5) Limited Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN120053645A (zh) 2018-06-01 2025-05-30 因赛特公司 治疗pi3k相关病症的给药方案
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법
WO2024233847A2 (en) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US990774A (en) * 1910-03-15 1911-04-25 John W P Reid Convertible core for building-blocks.
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4616019A (en) 1984-01-26 1986-10-07 Abbott Laboratories Naphthyridine antibacterial compounds
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US4810708A (en) 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
CA2001203C (en) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
CA2012681A1 (en) 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
JP3012684B2 (ja) * 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
EP0670320A4 (en) 1992-12-01 1997-05-02 Green Cross Corp DERIVATIVE OF 1,8-NAPHTHYRIDIN-2-ONE AND USE OF THIS DERIVATIVE.
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
CN1053668C (zh) 1994-06-14 2000-06-21 大日本制药株式会社 新型化合物及其制法和抗肿瘤剂
JP3242792B2 (ja) * 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
KR970705562A (ko) 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1997004779A1 (en) 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
ATE232863T1 (de) 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
EP0958297A1 (en) 1997-08-06 1999-11-24 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
KR20010005830A (ko) 1998-01-29 2001-01-15 도리이 신이치로 타입 ⅳ 포스포디에스테라제 억제활성을 지닌 1-사이클로알킬-1,8-나프틸리딘-4-온 유도체
KR100286874B1 (ko) * 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
AU4694999A (en) 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
WO2000016774A1 (fr) 1998-09-18 2000-03-30 Senju Pharmaceutical Co., Ltd. Procede de solubilisation de l'acide pyridonecarboxylique, solubilisant a cet effet, preparations de solutions aqueuses contenant de l'acide pyridonecarboxylique et leur procede de production
AU5213300A (en) 1999-05-19 2000-12-12 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
CA2407370A1 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
JP2005504808A (ja) * 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
US9885096B2 (en) 2012-02-24 2018-02-06 John Joseph Barsa Method and apparatus for high temperature production of metals

Also Published As

Publication number Publication date
RU2004112771A (ru) 2005-10-10
US20040157875A1 (en) 2004-08-12
GT200200194A (es) 2003-07-03
HRP20040309A2 (en) 2006-05-31
NO20041560L (no) 2004-05-11
PL369567A1 (en) 2005-05-02
PE20030549A1 (es) 2003-08-18
PL369531A1 (en) 2005-05-02
KR20040041178A (ko) 2004-05-14
NO20041567L (no) 2004-05-11
CN1578780A (zh) 2005-02-09
HUP0401889A2 (hu) 2005-01-28
US20060189609A1 (en) 2006-08-24
KR20040041177A (ko) 2004-05-14
ECSP045081A (es) 2004-06-28
MXPA04002136A (es) 2005-03-07
HRP20040317A2 (en) 2006-06-30
EP1432710A1 (en) 2004-06-30
JP2005504807A (ja) 2005-02-17
UY27456A1 (es) 2003-04-30
ZA200403064B (en) 2005-06-29
WO2003027112A1 (en) 2003-04-03
US20040014751A1 (en) 2004-01-22
US6964971B2 (en) 2005-11-15
RU2004112787A (ru) 2005-10-10
MA27079A1 (fr) 2004-12-20
EP1432711A1 (en) 2004-06-30
CO5560611A2 (es) 2005-09-30
US20040209866A1 (en) 2004-10-21
BR0212829A (pt) 2004-08-03
CN1578781A (zh) 2005-02-09
CA2461132A1 (en) 2003-04-03
CO5560542A2 (es) 2005-09-30
ECSP045084A (es) 2004-06-28
MXPA04002035A (es) 2004-06-07
PE20030601A1 (es) 2003-09-07
HUP0402310A2 (hu) 2005-02-28
BR0212864A (pt) 2004-08-17
JP2005504808A (ja) 2005-02-17
IL160707A0 (en) 2004-08-31
WO2003027113A1 (en) 2003-04-03
HN2002000275A (es) 2005-02-22
ZA200403063B (en) 2005-04-22
US6677352B1 (en) 2004-01-13
US7109196B2 (en) 2006-09-19
CA2463039A1 (en) 2003-04-03
MA26344A1 (fr) 2004-10-01
AR037503A1 (es) 2004-11-17
AR037504A1 (es) 2004-11-17
IL160708A0 (en) 2004-08-31
UY27457A1 (es) 2003-04-30
US6900205B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
GT200200191A (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
GT200100243A (es) Activadores heteroaromaticos fusionados de la glucoquinasa
GT200100146A (es) Activadores de glucoquinasa acetamida benzenica sustituida con atomos de alfa-acilo y alfa-heteroatomo.
AR027406A1 (es) Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias.
GT200300268A (es) Nuevos derivados fluoroglucosidos heterociclicos, medicamentos que contienen estos compuestos y el uso de los mismos
DK1379246T3 (da) Nocieptin-analoger
GT200300269A (es) Nuevos derivados fluoroglucosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
GT200200085A (es) Derivados de oxazol
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
ATE396186T1 (de) Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
GT200200286A (es) Nuevos derivados de pirido(2,1-a) isoquinolina
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
GT200300038A (es) Nuevos derivados de piridina y quinolina
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
GT200200122A (es) Imidazotriazinas
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
MX9307810A (es) Heterociclicos no aromaticos sustituidos con aminometileno.
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
DK1106178T3 (da) Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose